There’s another Canadian firm set to trade on the Nasdaq market. Bright Minds Bioscience (CSE: DRUG) this morning announced that it has been approved to begin trading on the major big board exchange.
The company will see its equity begin trading on the major US exchange as of November 8, where it will trade under the symbol “DRUG”, similar to its listing here in Canada. The firm will remain dual listed, with the move to not affect its listing on the Canadian Securities Exchange.
“Our listing on Nasdaq marks an important corporate milestone for Bright Minds, as we continue to advance our innovative drug candidates in pursuit of an improved generation of targeted serotonin-based therapies,” commented Ian McDonald, CEO of Bright Minds.
In making the announcement, McDonald identified that the move was made as it works to provide further liquidity for its shareholders, with the Nasdaq being the most liquid exchange globally.
Bright Minds is currently focused on developing novel psychedelic-based drugs for the targeted treatment of pain, epilepsy, and neuropsychiatric disorders. The firm is pushing towards in-human trials for BMB-101, it’s lead drug candidate, which focuses on the treatment of Dravet syndrome. Trials are expected to begin in the first half of 2022.
Bright Minds Bioscience last traded at $9.00 on the CSE.
FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.